Clinical Trials Directory

Trials / Completed

CompletedNCT04168580

Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
32 (actual)
Sponsor
AdventHealth Translational Research Institute · Academic / Other
Sex
All
Age
65 Years – 90 Years
Healthy volunteers
Accepted

Summary

The goal of this study is to define the effect of aging on brown adipose tissue mass in a cohort of older sedentary and older athlete adults.

Detailed description

Brown adipose tissue is a thermogenic tissue that contains large capacity to dissipate energy as heat. When activated by either cold-stimulation or increasing the amount of brown adipose tissue by transplantation, brown adipose tissue increases energy expenditure, decreases plasma glucose and lipids and improves systemic metabolism. Brown adipose tissue has great potential as a therapeutic target to combat both metabolic and cardiovascular disease, but brown adipose tissue decreases with age. The objective of this study is to define the effect of aging on brown adipose tissue mass in a cohort of older sedentary and older athlete adults. Studying the role of brown adipose tissue will potentially help us understand and prevent an accelerated aging process, which will help researchers better understand metabolic and cardiac health in the elderly.

Conditions

Interventions

TypeNameDescription
OTHERExercise Training InterventionOlder sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).

Timeline

Start date
2020-10-20
Primary completion
2024-02-23
Completion
2024-02-23
First posted
2019-11-19
Last updated
2025-07-14
Results posted
2025-07-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04168580. Inclusion in this directory is not an endorsement.